TY - JOUR
PY - 2023//
TI - Anticholinergic burden measures, symptoms, and fall-associated risk in older adults with polypharmacy: development and validation of a prognostic model
JO - PLoS one
A1 - Dinh, Truc Sophia
A1 - Meid, Andreas D.
A1 - Rudolf, Henrik
A1 - Brueckle, Maria-Sophie
A1 - González-González, Ana I.
A1 - Bencheva, Veronika
A1 - Gogolin, Matthias
A1 - Snell, Kym I. E.
A1 - Elders, Petra J. M.
A1 - Thuermann, Petra A.
A1 - Donner-Banzhoff, Norbert
A1 - Blom, Jeanet W.
A1 - van den Akker, Marjan
A1 - Gerlach, Ferdinand M.
A1 - Harder, Sebastian
A1 - Thiem, Ulrich
A1 - Glasziou, Paul P.
A1 - Haefeli, Walter E.
A1 - Muth, Christiane
SP - e0280907
EP - e0280907
VL - 18
IS - 1
N2 - BACKGROUND: Anticholinergic burden has been associated with adverse outcomes such as falls. To date, no gold standard measure has been identified to assess anticholinergic burden, and no conclusion has been drawn on which of the different measure algorithms best predicts falls in older patients from general practice. This study compared the ability of five measures of anticholinergic burden to predict falls. To account for patients' individual susceptibility to medications, the added predictive value of typical anticholinergic symptoms was further quantified in this context.
METHODS AND FINDINGS: To predict falls, models were developed and validated based on logistic regression models created using data from two German cluster-randomized controlled trials. The outcome was defined as "≥ 1 fall" vs. "no fall" within a 6-month follow-up period. Data from the RIME study (n = 1,197) were used in model development, and from PRIMUM (n = 502) for external validation. The models were developed step-wise in order to quantify the predictive ability of anticholinergic burden measures, and anticholinergic symptoms. In the development set, 1,015 patients had complete data and 188 (18.5%) experienced ≥ 1 fall within the 6-month follow-up period. The overall predictive value of the five anticholinergic measures was limited, with neither the employed anticholinergic variable (binary / count / burden), nor dose-dependent or dose-independent measures differing significantly in their ability to predict falls. The highest c-statistic was obtained using the German Anticholinergic Burden Score (0.73), whereby the optimism-corrected c-statistic was 0.71 after interval validation using bootstrapping and 0.63 in the external validation. Previous falls and dizziness / vertigo had the strongest prognostic value in all models.
CONCLUSIONS: The ability of anticholinergic burden measures to predict falls does not appear to differ significantly, and the added value they contribute to risk classification in fall-prediction models is limited. Previous falls and dizziness / vertigo contributed most to model performance.
Language: en
LA - en SN - 1932-6203 UR - http://dx.doi.org/10.1371/journal.pone.0280907 ID - ref1 ER -